Novel molecular targeted therapy for esophageal cancer.
Esophageal cancers are highly lethal neoplasms which are generally refractory to conventional multidisciplinary interventions. Recent elucidation of the mechanisms of esophageal carcinogenesis, as well as preclinical studies utilizing chromatin remodeling agents and inhibitors of oncogene signaling in conjunction with conventional chemotherapeutic agents provide new opportunities for the development of potentially efficacious molecular targeted therapies for these malignancies.
Schrump
David S
DS
Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bldg. 10, Rm. 4-3490, 10 Center Drive MSC 1201, Bethesda, MD 20892, USA. David_Schrump@nih.gov
Nguyen
Dao M
DM
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D000818:Animals; D017209:Apoptosis; D001471:Barrett Esophagus / Q000235:genetics / Q000473:pathology; D002471:Cell Transformation, Neoplastic; D002986:Clinical Trials as Topic; D019175:DNA Methylation; D047630:Depsipeptides / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006023:Glycoproteins / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000502:physiology; D017239:Paclitaxel / Q000494:pharmacology; D011493:Protein Kinase C / Q000502:physiology; D015398:Signal Transduction
D047630:Depsipeptides; D006023:Glycoproteins; D056572:Histone Deacetylase Inhibitors; C021240:tissue-factor-pathway inhibitor 2; D011493:Protein Kinase C; D020928:Mitogen-Activated Protein Kinases; D017239:Paclitaxel